|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/635 | (2006.01) |
| A61K 31/5377 | (2006.01) | ||
| A61P 35/02 | (2006.01) |
| (11) | Number of the document | 3704108 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18873778.7 |
| Date of filing the European patent application | 2018-10-30 | |
| (97) | Date of publication of the European application | 2020-09-09 |
| (45) | Date of publication and mention of the grant of the patent | 2024-04-24 |
| (46) | Date of publication of the claims translation | 2024-06-25 |
| (86) | Number | PCT/US2018/058194 |
| Date | 2018-10-30 |
| (87) | Number | WO 2019/089580 |
| Date | 2019-05-09 |
| (30) | Number | Date | Country code |
| 201762579502 P | 2017-10-31 | US |
| (72) |
BOOHER, Robert , US
|
| (73) |
Curis, Inc. ,
Ledgemont Research Center-Building C-500 Level
128 Spring Street, Lexington, MA 02421,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | IRAK4 inhibitorius derinyje su BCL-2 inhibitoriumi, skirti naudoti vėžio gydymui |
| IRAK4 INHIBITOR IN COMBINATION WITH A BCL-2 INHIBITOR FOR USE IN TREATING CANCER |
| Payment date | Validity (years) | Amount | |
| 2025-10-01 | 8 | 185.00 EUR |
| 2026-10-30 |